[ RadSafe ] Feinendegen piece searched

Sandy Perle sandyfl at cox.net
Sun Mar 25 15:42:01 CDT 2007


This is the abstract as found on the PubMed.gov site... stating that the
article should be published in April 2007. Perhaps one of the authors will
send you a copy (some do read Radsafe).

Whole-body responses to low-level radiation exposure: New concepts in
mammalian radiobiology.

Feinendegen LE, Pollycove M, Neumann RD.

Department of Nuclear Medicine, Heinrich-Heine University, Dusseldorf,
Germany; and Medical Department, Brookhaven National Laboratory, Upton, NY,

This review of low dose-induced whole-body effects, especially cancer,
shows: 1) Biological systems appear in hierarchy levels of organization,
from atoms to molecules, to cells, to tissues and organs, to the whole
system; 2) System responses to low-level exposures depend on: quality and
number of energy depositions in tissue micromasses (microdoses) being
potential triggers to damage and protection; time interval between two
microdose events per exposed micromass, that determines cellular responses
to the preceding microdose; and responses to microdose events in the system
being the target, with the balance between damage and benefit determining
the net effect; 3) System responses to acute or chronic low-level exposures
evolve from damage to the basic molecular level, mainly to DNA of stem
cells, and from adaptive responses that may occur in the whole body. Damage
may propagate to successive higher levels of organization, meeting
protective barriers which may become upregulated by adaptive responses. The
balance between damage and protection at each level per individual depends
on tissue dose. At single tissue doses below congruent with 0.1 Gy net
benefit tends to outweigh detriment. Thus, progression of damage to clinical
disease is not linear; 4) Quality and extent of system responses are under
genetic control. Thus, system net responses expectedly vary among
individuals; 5) The balance between health risk and benefit of low-level
exposure for a given individual may become predictable by gene-expression
profiles in control and irradiated cells of this individual; and 6) Clinical
trials applying individualized low-level irradiation are justified.

PMID: 17379086 [PubMed - in process]

Sandy Perle 
Senior Vice President, Technical Operations 
Global Dosimetry Solutions, Inc. 
2652 McGaw Avenue
Irvine, CA 92614

Tel: (949) 296-2306 / (888) 437-1714 Extension 2306 
Tel: (949) 419-1000 Extension 2306
Fax:(949) 296-1144

Global Dosimetry Website: http://www.dosimetry.com/ 
Personal Website: http://sandy-travels.com/ 

-----Original Message-----
From: radsafe-bounces at radlab.nl [mailto:radsafe-bounces at radlab.nl] On Behalf
Of Theo Richel
Sent: Sunday, March 25, 2007 1:31 PM
To: radsafe at radlab.nl
Subject: [ RadSafe ] Feinendegen piece searched

Would anyone have the following piece available as a pdf? A copy would be
much appreciated.

Exp Hematol. 2007 Apr;35(4 Suppl 1):37-46. Whole-body responses to low-level
radiation exposure: New concepts in mammalian radiobiology.  Feinendegen LE,
Pollycove M, Neumann RD.


Theo Richel
Stationsstraat 43
4421 AK Kapelle
theo at richel.org
Tel. +31 (0)113330030
Fax +31 (0)113330031

You are currently subscribed to the RadSafe mailing list

Before posting a message to RadSafe be sure to have read and understood the
RadSafe rules. These can be found at:

For information on how to subscribe or unsubscribe and other settings visit:

More information about the RadSafe mailing list